


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A heterocyclic compound represented by the formula I:



wherein X represents nitrogen atom or CH; Y represents C<sub>1</sub>-C<sub>6</sub> alkyl; R<sub>1</sub> represents morpholino (which may be substituted with one to four C<sub>1</sub>-C<sub>6</sub> alkyl); and R<sub>2</sub> and R<sub>3</sub> each represent hydrogen atom or C<sub>1</sub>-C<sub>6</sub> alkyl.

Claim 2 (Currently Amended): A compound as claimed in claim 1, wherein X is CH, Y ~~being~~ is methyl, R<sub>1</sub> ~~being~~ is morpholino, and each of R<sub>2</sub> and R<sub>3</sub> ~~being~~ is methyl.

Claim 3 (Original): A compound as claimed in claim 1, wherein the compound of the formula I is 2-(2-difluoromethyl-4-methoxybenzimidazol-1-yl)-4-(cis-2,6-dimethylmorpholino)-6-morpholinopyrimidine.

Claim 4 (Original): A compound as claimed in claim 1, wherein the compound of the formula I is 2-(2-difluoromethyl-4-methoxybenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholinopyrimidine.

Claim 5 (Currently Amended): An anti-malignant-tumor agent containing at least one compound as claimed in ~~claims 1 to 4~~ claim 1 as an effective component.

Claim 6 (Currently Amended): A pharmaceutical composition including at least one compound as claimed in ~~claims 1 to 4~~ claim 1 as an anti-malignant-tumor active component together with pharmaceutically acceptable diluent or carrier.